[ <sup>18</sup> F]SMBT‐1 PET as an Imaging Biomarker for Reactive Astrogliosis in Mild Cognitive Impairment and Alzheimer's Disease
[<sup>18</sup>F]SMBT-1 binding in the neocortex was elevated in patients with MCI and AD in association with Aβ accumulation, which is consistent with the results of plasma GFAP measurements. These findings suggest that [<sup>18</sup>F]SMBT-1 PET is a useful biomarker of reactive astrogliosis in the brain.
Authors
- A. Kikuchi
- MANABU TASHIRO
- Ryuichi Harada (ORCID: https://orcid.org/0000-0001-8538-8814)
- Shinobu Kawakatsu (ORCID: https://orcid.org/0000-0003-4074-1041)
- Shozo Furumoto (ORCID: https://orcid.org/0000-0002-9296-3079)
- Kotaro Hiraoka (ORCID: https://orcid.org/0000-0003-2422-3121)
- Ryota Kobayashi (ORCID: https://orcid.org/0000-0002-4213-618X)
- Aiko Ishiki
- H. Watabe
- Takashi Kato (ORCID: https://orcid.org/0000-0002-4293-4333)
- Takashi Nihashi (ORCID: https://orcid.org/0000-0002-5544-7649)
- Kazuko Takeda
- Berihu Mesfin
- Kenji Ishii
- Yingying Wu
- Nobuyuki Okamura
- Naoki Tomita
- Katsutoshi Furukawa
- Shunji Mugikura
Institutions
- Fukushima Medical University (JP)
- Tohoku University (JP)
- Tohoku University Hospital (JP)
- Tohoku Medical and Pharmaceutical University Hospital (JP)
- Tokyo Metropolitan Institute of Gerontology (JP)
- National Center for Geriatrics and Gerontology (JP)
- Yamagata University Hospital (JP)
- Tohoku Medical and Pharmaceutical University (JP)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70862_110311
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00